Search

everythinglearnresearchcommunity

for

Search:↓

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

The conversation discusses the effectiveness and systemic absorption of Topilutamide/Fluridil/Eucapil and topical Dutasteride for hair loss. Users are sharing their experiences and seeking success stories with these treatments.

The user wants to make a topical finasteride solution using wound cleanser with 70% IPA and add 40% propylene glycol due to headaches from minoxidil. They seek advice on using the wound cleanser and recommendations for pharmaceutical/cosmetic grade IPA in India.

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

The conversation discusses using Pyrilutamide, Alfatradiol 0.1%, and Minoxidil for hair loss treatment. Pyrilutamide is described as a strong antiandrogen, and Alfatradiol is noted for its effectiveness in inhibiting DHT on the scalp.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

Hair loss discussion includes finasteride intolerance and questioning if Pyrilutamide is an alternative. Pyrilutamide not commercially available, but may be tolerable if approved since it's not a 5aR inhibitor.

Treatments for hair loss, focusing on Fluridil/Topilutamide (Eucapil), Finasteride and RU58841 (Alfatradiol). The user reported that the Fluridil seemed to work well but had side effects of testicle ache, decreased mood and sex drive.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

The user is on their 5th week of using pyrilutamide for hair loss without experiencing side effects and has noticed slight hair growth. They also use minoxidil with finasteride and dutasteride as part of their treatment regimen.

A user shared their positive experience with hair regrowth using 1mg finasteride and 5% topical minoxidil daily, showing significant improvement in hair density over six months. The conversation includes supportive comments and questions about the treatment details, such as whether finasteride was taken orally or topically and if microneedling was used.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about choosing an additional topical treatment for hair loss, with options being fluridil, topical spiro, or alfatradiol, alongside existing treatments like dutasteride, oral minoxidil, latanoprost, and RU58841. Opinions vary on the effectiveness of adding these topicals, with some suggesting RU58841 is sufficient.

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

A user is experiencing increased hair shedding after using a homemade topical finasteride mixture with stemoxydine for six weeks. They are concerned about whether the low dose could cause shedding so early.

Pyrilutamide from RUdirect is discussed, with users sharing experiences and alternative sources like Koshinemall. Users mention using treatments like minoxidil, RU58841, and dutasteride for hair loss.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

A user on finasteride for hair loss is considering topical dutasteride to further reduce scalp DHT and is using various other topicals as substitutes for minoxidil due to concerns about the safety of their cats and potential heart side effects from oral minoxidil. They are exploring whether a once-weekly application of topical dutasteride would be effective.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

A 23-year-old male shared his 11-month progress using 1.25mg finasteride every other day and Nizoral/Dermazole, reporting reduced hair fall and new hair growth without major shedding. Users discussed the risks of finasteride for younger individuals and suggested consulting a doctor, with some recommending minoxidil as an alternative.

High-dose Dutasteride slightly reduces scalp itch, but adding RU58841 eliminates it completely. Some users report reduced itchiness and oiliness with Dutasteride, while others find topical anti-androgens more effective.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

The user experienced continuous hair shedding for 16 months while on finasteride, with periods of improvement. They also used T Gel shampoo and noticed a reduction in hair loss symptoms after 18 months, including the return of their sex drive and normal hair texture.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.